The once-booming life sciences real estate sector, a pandemic-era darling, is now facing unprecedented headwinds from declining federal research grants and a shift in venture capital investment, leading to record-high vacancies and market oversupply in major biotech hubs. This unexpected downturn is prompting developers to rethink their strategies, with potential long-term implications for scientific advancement.
The landscape of commercial real estate for lab spaces, once considered one of the hottest bets during the pandemic, is undergoing a dramatic shift. What was a rapidly expanding sector, driven by the urgent needs of the life sciences industry to combat COVID-19, is now confronting significant challenges. Landlords and developers are grappling with an environment where crucial funding sources from both Washington, D.C. and Silicon Valley are tightening, leading to unforeseen consequences across the industry.
At the heart of this disruption is a dual pressure: a significant pullback in federal research grants and a noticeable shift in venture capital investment. These two pillars are fundamental to the growth and sustainability of the life sciences sector, especially for the myriad of startups that eventually occupy these specialized lab facilities. As these funding channels constrict, the industry faces an oversupply of newly built lab spaces, particularly in top markets like Boston, the Bay Area, and San Diego.
The impact is tangible. For instance, developer IQHQ, a prominent San Diego-based landlord, acquired a 15-acre site in Redwood City, California, for $164 million in late 2021, with ambitious plans to build a trio of lab buildings. At the time, the future of life sciences real estate seemed limitless. However, IQHQ has since put the property up for sale, confirming a significant shift in market strategy, as reported by Business Insider. This move underscores a broader retreat in a segment that was once a high-flyer.
Beyond individual properties, the financial health of the sector is also visible in the stock market. Shares of Alexandria Real Estate Equities, a major publicly traded life sciences real estate company, have plummeted from a high of approximately $220 per share in late 2021 to around $80 today. This stark decline mirrors the growing concerns about the sector’s long-term prospects amidst funding uncertainties.
The Funding Famine: Federal Research Grants
One of the primary drivers of this downturn is a significant reduction in federal research funding. The National Institutes of Health (NIH), which is the largest grantor of federal money to the life sciences sector, is currently running about $5 billion behind on grant awards this year compared to 2024. This information comes from the Association of American Medical Colleges, highlighting a critical interruption in a decades-long partnership between the government and academia that fuels scientific progress.
These grants are not merely financial allocations; they are the “seeds of the exploratory research that may eventually move to a commercial product,” as noted by Heather Pierce, senior director for science policy and regulatory counsel at the Association of American Medical Colleges. Without this foundational federal support, the pipeline of innovative startups, which are the eventual tenants of these lab spaces, faces a severe bottleneck.
The repercussions are being felt directly by emerging companies. Louis Kassa, CEO of the Baruch S. Blumberg Institute, shared that four tenants at their Doylestown, Pennsylvania facility were recently denied Small Business Innovation Research (SBIR) grants from the NIH. Similarly, Mike Carnes, vice president for emerging company development at NCBiotech, a state-sponsored initiative in North Carolina, reported that ten startups in the state were rejected for approximately $15 million in SBIR funds. Adding to these concerns, a proposed executive budget by President Trump seeks a 40% cut in NIH funding, which would further exacerbate the situation for scientific research and, by extension, the demand for lab space.
Venture Capital’s New Focus
Concurrently, venture capital, another vital funding stream for the life sciences industry, has also retracted its support. Life sciences companies have collectively raised $24.9 billion in venture investment through September, placing 2025 on track for the lowest venture haul since before the pandemic, according to PitchBook. This pullback is occurring as other sectors, particularly Artificial Intelligence (AI), are attracting a substantial share of investment dollars.
The nature of VC funding in life sciences is also evolving. Kassa observed that venture capital is increasingly favoring larger, more established companies and advanced technologies over speculative startups. This strategic shift poses a significant challenge for the smaller, earlier-stage companies that typically drive initial demand for flexible lab spaces and incubators. The lack of early-stage investment means fewer new companies scaling up, directly impacting future demand for commercial lab real estate.
The Oversupply Crisis in Biotech Hubs
These funding challenges are compounded by a recent building boom that has left the market severely oversupplied. According to JLL, a leading real estate services firm, the average vacancy rate for life sciences spaces in major markets nationwide has skyrocketed from 6.6% in 2022 to a record 27% today. This figure even surpasses the national average office space vacancy rate of 22.5%, an area of commercial real estate already facing its own significant headwinds.
Notably, it’s the brand-new lab facilities that are bearing the brunt of these issues. Projects completed between 2022 and 2024 exhibit a staggering 48% vacancy rate, indicating a profound disconnect between new supply and current demand. The top three life sciences markets—Boston, the Bay Area, and San Diego—were magnets for new construction, accounting for 51.7 million square feet of the 70.8 million square feet built nationwide in the last five years. These hubs now face availability rates as high as 33% in Boston and San Diego, and 35% in the Bay Area, according to JLL.
Incubators Feeling the Pinch
Even incubators, which are typically more resilient to market fluctuations due to their focus on smaller, multi-tenant users, are experiencing significant strain. The Baruch S. Blumberg Institute, for example, has delayed expansion plans for its facilities in Doylestown, Pennsylvania, and Philadelphia due to increasing vacancies. The Pennsylvania Biotechnology Center, a space that has steadily grown over a decade and historically maintained full occupancy, now reports approximately 16% of its lab space as empty.
This situation underscores a unique market cycle, as described by Travis McCready, chair of JLL’s global life sciences advisory practice. He notes that in the past, downturns typically involved dips in either venture funding or stable federal funding, but rarely both at once. “This is the first cycle I can think of in my professional history where all of the black squirrel events are happening at the same time,” McCready remarked, emphasizing the unprecedented nature of the current challenges.
Adapting to the New Reality: Pivoting Lab Spaces
In response to these market shifts, some real estate investors are exploring alternative uses for their vacant lab spaces. John Grassi, CEO of Spear Street Capital, whose 500,000-square-foot lab building in Watertown, Massachusetts, purchased for $300 million in 2020, has sat largely vacant, is now considering converting the property for other purposes. These potential new uses include applications for AI in life sciences or even drug manufacturing.
Grassi remains optimistic about finding innovative solutions, reflecting a broader sentiment of adaptation within the industry. The future of life sciences real estate may involve a diversification of space utilization, driven by technological advancements and the shifting needs of a sector undergoing profound transformation. For the fan community of scientific innovation and biotech, these real estate dynamics are not just about buildings, but about the very infrastructure supporting the next generation of medical breakthroughs.
